Asterias Biotherapeutics (NYSEAMERICAN:AST) has been assigned a $11.00 price objective by equities researchers at HC Wainwright in a research note issued to investors on Monday, January 8th. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 348.98% from the company’s previous close.
Separately, Zacks Investment Research cut shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $8.94.
Shares of Asterias Biotherapeutics (AST) opened at $2.45 on Monday. Asterias Biotherapeutics has a 52 week low of $1.95 and a 52 week high of $5.00. The stock has a market cap of $132.67, a P/E ratio of -3.77 and a beta of 1.30.
WARNING: “Asterias Biotherapeutics (NYSEAMERICAN:AST) Given a $11.00 Price Target by HC Wainwright Analysts” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/asterias-biotherapeutics-ast-rating-reiterated-by-hc-wainwright/1813935.html.
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.